Related Experiment Video
Updated: Aug 18, 2026
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
Published on: May 1, 2020
Use of mitomycin C for treatment of keloid: a preliminary report
Yoav P Talmi1, Arie Orenstein, Michael Wolf
1Department of Otolaryngology--Head and Neck Surgery, Chaim Sheba Medical Center, Tel Hashomer, Israel. yoav.talmi@sheba.health.gov.il
Objectives:
Mitomycin C (MC) is an anti-neoplastic agent with an anti-proliferative effect on fibroblasts. We set out to evaluate the effect of MC application following keloid excision.
Study Design And Setting:
Patients with keloid in a tertiary referral center were enrolled in a prospective study. The scar was excised and prior to skin closure, a pledget with 1 cc of MC 0.4 mg/mL was applied for 5 minutes. Patient satisfaction and keloid thickness were assessed.
Results:
All patients were satisfied with the results, although complete disappearance of the keloid was evident only in two. Keloid thickness was measured and ranged from 5 to 26 mm. Following surgery and treatment at 2 months thickness ranged from 0 to 8 mm.
Conclusions:
MC application following scar resection appears to be effective in treatment of keloid.
Significance:
As no specific effective treatment for keloid is currently available, utilization of this readily available therapeutic agent may improve treatment outcome.
